<DOC>
	<DOC>NCT02597439</DOC>
	<brief_summary>The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.</brief_summary>
	<brief_title>Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe</brief_title>
	<detailed_description>PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects in the age range of 13-20 years with a higher chance of developing psychosis, as determined by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in conducted at 18 sites in 9 countries.</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>Written informed consent of the subject. For individuals younger than 18 years of age the parents / legal representatives need to give consent, and the subject can provide assent (whether the latter is required depends on local laws and regulations). UHR diagnosis as made using the Comprehensive Assessment of AtRisk Mental States (CAARMS) (Yung et al., 2005). Subjects have to meet one or more of the following criteria: (a) attenuated psychotic symptoms, (b) brief limited intermittent psychotic symptoms (a history of one or more episodes of frank psychotic symptoms that resolved spontaneously within 1 week in the past year), or (c) either the presence of schizotypal personality disorder or a family history of psychosis in a firstdegree relative, all three together with a recent decline in function. Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial. Laboratory screening values considered clinically relevant by a medical doctor for transaminases, thyroid hormones or coagulation parameters Current or past DSMIV diagnosis of psychosis, as measured with KSADSPL Current treatment with an antipsychotic or moodstabilising agent Intake of an antipsychotic or moodstabilising agent in the two weeks prior to study inclusion Intake of an antipsychotic agent equivalent to a total haloperidol use of &gt;50 mg in the six months prior to study inclusion A firstdegree relative (i.e. parents, offspring or siblings) participating in this study UHR diagnosis on the basis of attenuated psychotic symptoms that are entirely explained by acute intoxication Current aggression or dangerous behaviour (PANSS G14 score 5 or above) Current suicidality / selfharm (PANSS G6 score 7) Current DSMIV diagnosis of alcohol or substance dependence as measured with KSADSPL Any current or previous neurological disorder, including epilepsy History of head injury resulting in unconsciousness lasting at least 1 hour IQ &lt; 70 More than 4 weeks of regular omega3 supplementation (&gt;2 daily capsules standard strength providing &gt;600 mg combined EPA/DHA) within the last 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ultra-high risk</keyword>
	<keyword>UHR</keyword>
	<keyword>psychosis</keyword>
</DOC>